Gabriele Pecher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7553764/publications.pdf

Version: 2024-02-01

18	1,112	758635 12	887659 17
papers	citations	h-index	g-index

19	19	19	1555
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HCMV-Mediated Interference of Bortezomib-Induced Apoptosis in Colon Carcinoma Cell Line Caco-2. Viruses, 2021, 13, 83.	1.5	4
2	Engineering NK Cells for CAR Therapyâ€"Recent Advances in Gene Transfer Methodology. Frontiers in Immunology, 2020, 11, 611163.	2.2	53
3	Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. Molecular Therapy, 2017, 25, 1248-1258.	3.7	305
4	Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. Molecular and Clinical Oncology, 2017, 7, 151-157.	0.4	22
5	Pattern of the Epitope-Specific IgG/IgM Response against Human Cytomegalovirus in Patients with Multiple Myeloma. Vaccine Journal, 2013, 20, 1298-1304.	3.2	6
6	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. European Journal of Cancer, 2010, 46, 2926-2935.	1.3	149
7	Oral administration of a soluble 1â€“3, 1â€“6 Î²-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice. International Immunopharmacology, 2009, 9, 1298-1303.	1.7	18
8	Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 141-145.	1.0	7
9	Cellular and Humoral Immunogenicity of Hamster Polyomavirus-Derived Virus-Like Particles Harboring a Mucin 1 Cytotoxic T-Cell Epitope. Viral Immunology, 2008, 21, 12-26.	0.6	16
10	Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology, 2006, 354, 252-260.	1.1	27
11	Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leukemia Research, 2005, 29, 301-306.	0.4	43
12	Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunology, Immunotherapy, 2002, 51, 669-673.	2.0	144
13	Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Therapy, 2002, 9, 390-398.	2.2	36
14	Generation of an Immortalized Human CD4+ T Cell Clone Inhibiting Tumor Growth in Mice. Biochemical and Biophysical Research Communications, 2001, 283, 738-742.	1.0	5
15	Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer. Cancer Immunology, Immunotherapy, 2001, 50, 549-556.	2.0	11
16	Expression of mucin (MUC-1) from a Mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. Journal of Gene Medicine, 1999, 1, 84-92.	1.4	15
17	Expression of mucin (MUC-1) from a Mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. , 1999, 1, 84.		1
18	MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines. Immunological Reviews, 1995, 145, 61-89.	2.8	250